All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results PRINCIPLE, 2021 1.65 [0.03; 83.12]
1.65 [0.03 ; 83.12 ] PRINCIPLE, 2021 1 0% 1,323 NA not evaluable hospitalization or deathdetailed results Hinks (ATOMIC2), 2021 0.91 [0.43; 1.92]
0.91 [0.43 ; 1.92 ] Hinks (ATOMIC2), 2021 1 0% 292 NA not evaluable A EFFACER PCR-negative (end of follow-up)detailed results Hinks (ATOMIC2), 2021 0.91 [0.57; 1.46]
0.91 [0.57 ; 1.46 ] Hinks (ATOMIC2), 2021 1 0% 295 NA not evaluable clinical improvementdetailed results PRINCIPLE, 2021 1.08 [0.95; 1.23]
1.08 [0.95 ; 1.23 ] PRINCIPLE, 2021 1 0% 1,323 NA not evaluable clinical improvement (14-day)detailed results ACTION, 2021 1.01 [0.75; 1.37]
1.01 [0.75 ; 1.37 ] ACTION, 2021 1 0% 263 NA not evaluable clinical improvement (time to event analysis only)detailed results PRINCIPLE, 2021 1.08 [0.95; 1.23]
1.08 [0.95 ; 1.23 ] PRINCIPLE, 2021 1 0% 1,323 NA not evaluable hospitalizationdetailed results Hinks (ATOMIC2), 2021 0.95 [0.46; 1.96]
PRINCIPLE, 2021 0.94 [0.50; 1.75]
0.94 [0.59 ; 1.51 ] Hinks (ATOMIC2), 2021, PRINCIPLE, 2021 2 0% 1,618 moderate not evaluable mechanical ventilationdetailed results PRINCIPLE, 2021 0.50 [0.10; 2.60]
0.50 [0.10 ; 2.60 ] PRINCIPLE, 2021 1 0% 1,121 NA not evaluable ICU admissiondetailed results PRINCIPLE, 2021 0.76 [0.18; 3.18]
0.76 [0.18 ; 3.18 ] PRINCIPLE, 2021 1 0% 1,120 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-08-20 21:25 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 97
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290